Ampio Pharmaceuticals begins phase 1 trial of Ampion for COVID-19 treatment
Ampio Pharmaceuticals has started a phase 1 clinical trial in the US for assessing its immunomodulatory anti-inflammatory agent Ampion as a five-day intravenous (IV) treatment for COVID-19 in adult patients who need supplemental oxygen. According to the Colorado-based biopharma company, the primary endpoint for the randomized, controlled study – NCT04456452 is the safety and tolerability […]